13. ICW-Süd/ HWX-Kongress (Hygiene and Wound Congress: One Health) from 28^th to 30^th June 2022 (near Wurzburg)

28^th training week for practical dermatology and venereology from 12^th to 16^th July 2022 in Munich

debra Care Conference from 17^th to 20^th July 2022 in Denver, Colorado, USA

3^rd WundD.A.CH three-country congress from 29^th September to 1^st October 2022 in Stuttgart

05^th Nuremberg Wound Congress from 1^st to 2^nd December 2022 in Nuremberg

Our daughter company RHEACELL has been granted national marketing authorization (§ 4b of the German Medicinal Products Act) in Germany for its cell therapy product AMESANAR®, produced by TICEBA, for the use in patients with chronic wounds.

Drawing on over 15 years' experience in advanced stem cell research and regenerative medicine to pioneer the production of ABCB5-positive (ABCB5+) mesenchymal stem cells and innovative treatment pathways.

Using cutting-edge, in-house process technology and quality control systems to generate state-of-the-art ABCB5+ mesenchymal stem cells ("H.F.M Stem Cells") and ATMP (Advanced Therapy Medicinal Products) in line with AMG (German Medicinal Products Act) requirements.

Science-based mechanisms-of-action translated into GMP-validated potency assays and release criteria to predict clinical efficacy.

High through-put stem cell production based on globally patented technology and expertise - catering for world-wide market needs - anytime, anyplace, anywhere.

Our tried and tested patented technology platform nurturing next-generation technologies (CRISPR/Cas, iPS Technology and 3D Bioprinting), heralding the arrival of next-generation cell therapies.

TICEBA - exclusive licensee of the full ABCB5 patent portfolio from Boston Children's Hospital - a teaching affiliate of Harvard Medical School, Boston, Massachusetts. Several of these were invented at the same time and are jointly owned by TICEBA.